BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 8921778)

  • 1. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
    Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
    Topol EJ; Fuster V; Harrington RA; Califf RM; Kleiman NS; Kereiakes DJ; Cohen M; Chapekis A; Gold HK; Tannenbaum MA
    Circulation; 1994 Apr; 89(4):1557-66. PubMed ID: 8149521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.
    Scharfstein JS; Abendschein DR; Eisenberg PR; George D; Cannon CP; Becker RC; Sobel B; Cupples LA; Braunwald E; Loscalzo J
    Am J Cardiol; 1996 Sep; 78(5):503-10. PubMed ID: 8806332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina.
    Mombelli G; Marchetti O; Haeberli A; Straub PW
    Am Heart J; 1998 Dec; 136(6):1106-13. PubMed ID: 9842027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
    Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
    Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.
    Lidón RM; Théroux P; Juneau M; Adelman B; Maraganore J
    Circulation; 1993 Oct; 88(4 Pt 1):1495-501. PubMed ID: 8403297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
    Merlini PA; Ardissino D; Rosenberg RD; Colombi E; Agricola P; Oltrona L; Ottani F; Galvani M; Bauer KA; Bottasso B; Bertocchi F; Mannucci PM
    Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2162-6. PubMed ID: 10978264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
    Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
    van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW
    Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
    Yusuf S
    Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
    N Engl J Med; 1996 Sep; 335(11):775-82. PubMed ID: 8778585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina.
    Rupprecht HJ; Terres W; Ozbek C; Luz M; Jessel A; Hafner G; vom Dahl J; Kromer EP; Prellwitz W; Meyer J
    J Am Coll Cardiol; 1995 Dec; 26(7):1637-42. PubMed ID: 7594097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass.
    Bernabei A; Rao AK; Niewiarowski S; Colman RW; Sun L; Edmunds LH
    J Thorac Cardiovasc Surg; 1994 Aug; 108(2):381-2. PubMed ID: 8041187
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.